Elebsiran not checked

Vir Biotechnology, Inc. · VIR-2218

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
10 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
Tested for
Viral Hepatitis (3 trials), Hepatitis D, Chronic
Main trialPhase 3
“This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.”In the company’s words, NCT06903338 on ClinicalTrials.gov
Other names
VIR-2218

Other drugs for Viral Hepatitis

All 60 drugs for Viral Hepatitis

Coming up3

Changes1

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Sep 2026 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Phase 3Active, not recruiting Dec 2026 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Phase 2Active, not recruiting Mar 2029 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Phase 2Active, not recruiting Nov 2031 SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Phase 2Completed 25 Mar 2024 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Phase 2Completed 16 Mar 2026 Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Phase 1/2Completed 3 Sep 2020 Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
Phase 1/2Completed 15 Oct 2024 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
Phase 1Completed 1 Mar 2025 A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
Phase 1Completed 9 Dec 2025 Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Elebsiran

Following is part of Solo: you see every change to Elebsiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in